サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1435117

抗血小板薬市場：薬剤タイプ、投与方法、用途、エンドユーザー別-2024-2030年の世界予測

Antiplatelet Market by Drug Type (Abciximab, Aspirin, Clopidogrel), Mode of Administration (Intravenous, Oral, Rectal), Application, End User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 198 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗血小板薬市場：薬剤タイプ、投与方法、用途、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗血小板薬市場規模は2023年に13億1,000万米ドルと推計され、2024年には14億米ドルに達し、CAGR 7.28%で2030年には21億5,000万米ドルに達すると予測されます。

抗血小板薬の世界市場

主な市場の統計
基準年[2023］ 13億1,000万米ドル
予測年[2024］ 14億米ドル
予測年 [2030] 21億5,000万米ドル
CAGR（%） 7.28%
抗血小板薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗血小板薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗血小板薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-抗血小板薬市場の市場規模および予測は？

2-抗血小板薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-抗血小板薬市場における技術動向と規制の枠組みは？

4-抗血小板薬市場における主要ベンダーの市場シェアは？

5-抗血小板薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 慢性心血管疾患の有病率の上昇
      • 血栓溶解性イベントの頻度の増加と抗血栓薬の必要性
      • 政府による好ましい抗血小板薬医薬品承認
    • 抑制要因
      • 高額な治療費と補償金の欠如
    • 機会
      • 新しい抗血小板薬医薬品の大規模な研究開発と臨床試験
      • 精密医療における抗血小板薬療法の可能性
    • 課題
      • 抗血小板薬薬物に対する血液をサラサラにする薬という誤解と、有効性と安全性に関する懸念
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗血小板薬市場薬剤の種類別

  • アブシキシマブ
  • アスピリン
  • クロピドグレル
  • ジピリダモール
  • プラスグレル
  • チカグレロル
  • チクロピジン
  • ティロフィバン

第7章 抗血小板薬市場管理モード別

  • 静脈内
  • オーラル
  • 直腸

第8章 抗血小板薬市場：用途別

  • 血管形成術
  • 動脈血栓症
  • 歯科手術
  • 心筋梗塞
  • 経皮的冠動脈インターベンション

第9章 抗血小板薬市場：エンドユーザー別

  • 外来手術センター
  • 診療所
  • 緊急サービスセンター
  • 病院

第10章 南北アメリカの抗血小板薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の抗血小板薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの抗血小板薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Alta Laboratories Ltd.
    • Amgen Inc.
    • AstraZeneca PLC
    • Baxter International Inc.
    • Bayer AG
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • CSL Behring LLC
    • Daiichi Sankyo Company, Limited
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F.Hoffmann-La Roche AG
    • Genentech, Inc.
    • Gilead Sciences, Inc.
    • Glaxosmithkline PLC
    • Johnson & Johnson Services, Inc
    • Ligand Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • Sanofi S.A
    • Takeda Pharmaceutical Company Limited
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTIPLATELET MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIPLATELET MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIPLATELET MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIPLATELET MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIPLATELET MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIPLATELET MARKET DYNAMICS
  • FIGURE 7. ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIPLATELET MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. ANTIPLATELET MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. ANTIPLATELET MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. ANTIPLATELET MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ANTIPLATELET MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES ANTIPLATELET MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ANTIPLATELET MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. ANTIPLATELET MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIPLATELET MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIPLATELET MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPLATELET MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIPLATELET MARKET SIZE, BY ABCIXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIPLATELET MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIPLATELET MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIPLATELET MARKET SIZE, BY DIPYRIDAMOLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIPLATELET MARKET SIZE, BY PRASUGREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIPLATELET MARKET SIZE, BY TICAGRELOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIPLATELET MARKET SIZE, BY TICLOPIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIPLATELET MARKET SIZE, BY TIROFIBAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIPLATELET MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIPLATELET MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIPLATELET MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIPLATELET MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIPLATELET MARKET SIZE, BY ARTERIAL THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIPLATELET MARKET SIZE, BY DENTAL SURGERIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIPLATELET MARKET SIZE, BY MYOCARDIAL INFRACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIPLATELET MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIPLATELET MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANTIPLATELET MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. ANTIPLATELET MARKET SIZE, BY EMERGENCY SERVICE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. ANTIPLATELET MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIPLATELET MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTIPLATELET MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTIPLATELET MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTIPLATELET MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ANTIPLATELET MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM ANTIPLATELET MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM ANTIPLATELET MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM ANTIPLATELET MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. ANTIPLATELET MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 198. ANTIPLATELET MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 199. ANTIPLATELET MARKET LICENSE & PRICING
目次
Product Code: MRR-CA17E905E96D

[198 Pages Report] The Antiplatelet Market size was estimated at USD 1.31 billion in 2023 and expected to reach USD 1.40 billion in 2024, at a CAGR 7.28% to reach USD 2.15 billion by 2030.

Global Antiplatelet Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.31 billion
Estimated Year [2024] USD 1.40 billion
Forecast Year [2030] USD 2.15 billion
CAGR (%) 7.28%
Antiplatelet Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antiplatelet Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antiplatelet Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antiplatelet Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alta Laboratories Ltd., Amgen Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, CSL Behring LLC, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F.Hoffmann-La Roche AG, Genentech, Inc., Gilead Sciences, Inc., Glaxosmithkline PLC, Johnson & Johnson Services, Inc, Ligand Pharmaceuticals Inc., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Antiplatelet Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Abciximab
    • Aspirin
    • Clopidogrel
    • Dipyridamole
    • Prasugrel
    • Ticagrelor
    • Ticlopidine
    • Tirofiban
  • Mode of Administration
    • Intravenous
    • Oral
    • Rectal
  • Application
    • Angioplasty
    • Arterial Thrombosis
    • Dental Surgeries
    • Myocardial Infraction
    • Percutaneous Coronary Interventions
  • End User
    • Ambulatory Surgical Centers
    • Clinic
    • Emergency Service Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antiplatelet Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antiplatelet Market?

3. What are the technology trends and regulatory frameworks in the Antiplatelet Market?

4. What is the market share of the leading vendors in the Antiplatelet Market?

5. Which modes and strategic moves are suitable for entering the Antiplatelet Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antiplatelet Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic cardiovascular diseases
      • 5.1.1.2. Growing frequency of thrombolytic events and need for antithrombotic drugs
      • 5.1.1.3. Favorable antiplatelet drugs approvals by governments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and lack of reimbursements
    • 5.1.3. Opportunities
      • 5.1.3.1. Extensive research and development and clinical trials of novel antiplatelet drugs
      • 5.1.3.2. Potential of antiplatelet therapy in precision medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Misconception of antiplatelet drugs as blood-thinning drugs and concerns related to efficacy and safety
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antiplatelet Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Abciximab
  • 6.3. Aspirin
  • 6.4. Clopidogrel
  • 6.5. Dipyridamole
  • 6.6. Prasugrel
  • 6.7. Ticagrelor
  • 6.8. Ticlopidine
  • 6.9. Tirofiban

7. Antiplatelet Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Rectal

8. Antiplatelet Market, by Application

  • 8.1. Introduction
  • 8.2. Angioplasty
  • 8.3. Arterial Thrombosis
  • 8.4. Dental Surgeries
  • 8.5. Myocardial Infraction
  • 8.6. Percutaneous Coronary Interventions

9. Antiplatelet Market, by End User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Clinic
  • 9.4. Emergency Service Centers
  • 9.5. Hospitals

10. Americas Antiplatelet Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antiplatelet Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antiplatelet Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. Alta Laboratories Ltd.
    • 14.1.3. Amgen Inc.
    • 14.1.4. AstraZeneca PLC
    • 14.1.5. Baxter International Inc.
    • 14.1.6. Bayer AG
    • 14.1.7. Biogen Inc.
    • 14.1.8. Boehringer Ingelheim International GmbH
    • 14.1.9. Bristol-Myers Squibb Company
    • 14.1.10. CSL Behring LLC
    • 14.1.11. Daiichi Sankyo Company, Limited
    • 14.1.12. Eisai Co., Ltd.
    • 14.1.13. Eli Lilly and Company
    • 14.1.14. F.Hoffmann-La Roche AG
    • 14.1.15. Genentech, Inc.
    • 14.1.16. Gilead Sciences, Inc.
    • 14.1.17. Glaxosmithkline PLC
    • 14.1.18. Johnson & Johnson Services, Inc
    • 14.1.19. Ligand Pharmaceuticals Inc.
    • 14.1.20. Merck & Co., Inc.
    • 14.1.21. Novartis AG
    • 14.1.22. Otsuka Pharmaceutical Co., Ltd.
    • 14.1.23. Pfizer Inc.
    • 14.1.24. Sanofi S.A
    • 14.1.25. Takeda Pharmaceutical Company Limited
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing